Business Context and Reporting Period
Company: Humacyte, Inc. (HUMA)
Filing Type: Form 8-K (Current Report)
Date of Report: December 15, 2025
Event: Entry into a Material Definitive Agreement and creation of a direct financial obligation involving a senior secured term loan facility and the issuance of unregistered warrants.
Key Financial Metrics and Transaction Terms
Debt Facility:
- Total Facility Size: Up to $77,500,000.
- Initial Funding (First Tranche): $40,000,000 (fully funded on Closing Date).
- Delayed Draw (Second Tranche): $12,500,000 (available Oct 1, 2026 – Mar 31, 2027, subject to conditions).
- Delayed Draw (Third Tranche): $25,000,000 (available Jul 1, 2027 – Jun 30, 2028, subject to conditions).
- Maturity Date: December 1, 2029.
- Interest Rate: Greater of 11.50% or WSJ Prime Rate + 4.50%.
- Repayment Terms: Interest-only monthly payments initially; amortization begins Dec 1, 2027 (or Dec 1, 2028 if Second Tranche is drawn).
- Prepayment Premiums: 3.0% (Year 1), 2.0% (Year 2), 1.0% (Year 3+).
- Collateral: Substantially all assets of the Company and its subsidiaries.
Equity Component (Warrant):
- Underlying Value: Up to $5,037,500 ($3,412,500 initial + $1,625,000 upon Third Tranche funding).
- Exercise Price: Lower of $1.28 or the lowest effective sale price in a bona fide offering prior to March 31, 2026.
- Expiration: December 15, 2030.
- Beneficial Ownership Limit: 4.99% (or up to 9.99% with consent).
Conversion Option: Lenders may elect to convert up to $2,500,000 of principal into common stock at 130% of the Warrant Price.
Financial Performance: The filing text does not provide revenue, profit, cash flow, or margin data for the reporting period.
Material Changes and Use of Proceeds
Use of Proceeds: Working capital, general business requirements, and repayment of existing indebtedness under a prior Purchase Agreement.
Covenants: The agreement includes customary affirmative covenants (financial reporting, liquidity requirements) and negative covenants (restrictions on mergers, additional indebtedness, and liens).
Events of Default: Standard provisions apply; a continuing default may require immediate repayment of all outstanding amounts.
Guidance, Risks, and Contingencies
Conditions Precedent: The Second and Third Tranche loans are contingent upon the satisfaction of specific revenue targets, regulatory approvals, and liquidity conditions.
Risks:
- Dilution: Potential issuance of shares via warrant exercise or debt conversion.
- Liquidity Constraints: Strict covenants and collateralization of substantially all assets.
- Prepayment Costs: Significant penalties for early repayment in the first three years.
Management Commentary: The filing contains no forward-looking guidance or management commentary beyond the transaction terms.
Key Facts for Investor Verification
- Verify the specific revenue and regulatory milestones required to access the $37.5 million in delayed draw tranches.
- Confirm the current status of the "existing Purchase Agreement" being repaid with the initial $40 million tranche.
- Monitor the stock price relative to the $1.28 warrant exercise price floor and potential downward adjustments based on future bona fide offerings before March 31, 2026.
- Assess the impact of the 11.50%+ interest rate and amortization schedule on future cash flow requirements.
- Review the full text of the Loan Agreement (Exhibit 10.1) for specific definitions of "liquidity requirements" and "regulatory approvals."